U.S. Rep. Kathy Castor urges more transparency with price hikes by drug manufacturers
After calling for a congressional hearing last week on the outrageous cost increases by Mylan corporation for the price of the EpiPen, today U.S. Rep. Kathy Castor (FL14) cosponsored bipartisan and bicameral legislation to address skyrocketing prescription drug price increases by corporations. The FAIR Drug Pricing Act would require basic transparency for pharmaceutical corporations that increase drug prices by more than 10 percent a year.